

13<sup>th</sup> November, 2020

То,	То,
BSE Limited,	The Manager,
25, P. J. Towers,	Listing Department,
Dalal Street,	National Stock Exchange of India Ltd.,
Mumbai – 400 001	Exchange Plaza, Bandra Kurla Complex,
Ref: Company Scrip Code: 532834	Bandra (East), Mumbai- 400051
	Ref: Symbol: CAMLINFINE    Series: EQ

### Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - ("SEBI LODR")

This is in continuation to our disclosure dated November 9, 2020 in relation to the conference call with various domestic and international investors and analysts organized by Edelweiss – Professional Investor Research to discuss the financial results of the Company for the quarter ended September 30, 2020 (Q2) on November 13, 2020, please find enclosed herewith the investor presentation made for the aforesaid call.

It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the investor presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.


We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.

Thanking You, Encl.: a/a. For **Camlin Fine Sciences Limited** 

and Godbole

Mandar Godbole Company Secretary & Compliance Officer







### Camlin Fine Sciences

Bringing science to everyday life

### EARNINGS PRESENTATION

HI / Q2-FY2I

# Snapshot



One of the few vertically and backward integrated players	Leading Manufacturers of Antioxidants in the world with more than 30 years of experience	3 <sup>rd</sup> largest producer of Vanillin in the world
Serving more than 80 countries with over 100 products	Preferred Partner for manufacturing customized products	Strategic move to start blends which have higher margins
5 Manufacturing Facilities, 2 R&D Centres and 5 Application Labs	Global expertise, local solutions	Strong management team with experienced industry professionals

# About the Company

- In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror shareholding) the fine chemical business from Camlin Ltd.
- The Company has over 30 years of experience providing innovative solutions with a competitive advantage in fine sciences.
- CFS is a vertically integrated company, engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors.

Food, feed, animal and pet nutrition

Pharma


**Petro Chemicals** 

**Polymers** 


Flavours & Fragrance Agro Chemicals Dyes and Pigments Bio Diesel

- CFS categorizes their business into 3 different verticals based on their product portfolio, namely: Shelf-Life Solutions (which include anti-oxidants, its blends and additives), Performance chemicals and Aroma Chemicals.
- CFS has subsidiaries in Mexico, North America, China, Europe and Brazil serving in more than 80 countries with more than 100 products and over 1,000 satisfied customers.
- CFS markets its products in Europe, Asia Pacific (including India), North Africa, Middle East, South, Central and North America.





HI-FY2I Operational Revenue Breakup





Fine Sciences



### HI / Q2-FY21 FINANCIAL OVERVIEW

## HI / Q2-FY21 Financial and Operational Highlights



Q2-FY21 Financial Highlights (Standalone):	Q2-FY21 Financial Highlights (Consolidated):
Turnover: INR 1,468 Mn	Turnover: INR 2,568 Mn
EBITDA: INR 71 Mn	EBITDA: INR 336 Mn
• EBITDA Margin : 4.84%	EBITDA Margin: 13.08%
Adjusted EBITDA*: INR 144 Mn	Adjusted EBITDA*: INR 425 Mn
• <b>PBT:</b> INR (9) Mn	• <b>PBT:</b> INR 172 Mn
• <b>PAT:</b> INR (10) Mn	• <b>PAT:</b> INR 97 Mn
PAT Margins: NA	PAT Margins: 3.78%
HI-FY21 Financial Highlights (Standalone):	HI-FY2I Financial Highlights (Consolidated):
<ul> <li>HI-FY21 Financial Highlights (Standalone):</li> <li>Turnover: INR 2,679 Mn</li> </ul>	<ul> <li>HI-FY2I Financial Highlights (Consolidated):</li> <li>Turnover: INR 5,626 Mn</li> </ul>
• Turnover: INR 2,679 Mn	• Turnover: INR 5,626 Mn
<ul> <li>Turnover: INR 2,679 Mn</li> <li>EBITDA: INR 233 Mn</li> </ul>	<ul> <li>Turnover: INR 5,626 Mn</li> <li>EBITDA: INR 848 Mn</li> </ul>
<ul> <li>Turnover: INR 2,679 Mn</li> <li>EBITDA: INR 233 Mn</li> <li>EBITDA Margin: 8.70%</li> </ul>	<ul> <li>Turnover: INR 5,626 Mn</li> <li>EBITDA: INR 848 Mn</li> <li>EBITDA Margin: 15.07%</li> </ul>
<ul> <li>Turnover: INR 2,679 Mn</li> <li>EBITDA: INR 233 Mn</li> <li>EBITDA Margin : 8.70%</li> <li>Adjusted EBITDA*: INR 302 Mn</li> </ul>	<ul> <li>Turnover: INR 5,626 Mn</li> <li>EBITDA: INR 848 Mn</li> <li>EBITDA Margin : 15.07%</li> <li>Adjusted EBITDA*: INR 968 Mn</li> </ul>

### **Operational Highlights (Standalone and Consolidated)**

- Margins in India were affected due to strengthening of rupee & change in product mix. While the consolidated margins were higher due to favourable product mix.
- In the current quarter, Other expenditure include foreign exchange loss of INR 73.21 million and INR 88.52 million for standalone and consolidated respectively.
- Commercial production of Diphenol Plant at Dahej started on September 21, 2020.

\* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)

## Q2-FY21 Standalone Income Statement (Ind-AS)



Income Statement (Mn)	Q2-FY21	Q2-FY20	Y-o-Y	QI-FY2I	Q-0-Q
Operational Revenue	I,468	I,435	2.3%	1,212	21.1%
Total Expenses	١,397	1,255	11.3%	1,049	33.2%
Operational EBITDA	71	180	(60.6)%	163	(56.4)%
Operational EBITDA Margins (%)	4.84%	12.54%	(770) Bps	13.45%	(861) Bps
Adjusted EBITDA*	144	180	(20.0)%	163	(11.7)%
Adjusted EBITDA Margins (%)	9.81%	12.54%	(273) Bps	13.45%	(364) Bps
Other Income	13	55	(76.4)%	10	30.0%
Depreciation	34	28	21.4%	31	9.7%
Finance Cost	59	89	(33.7)%	86	(31.4)%
Exceptional Items	-	-	NA	5	NA
PBT	(9)	118	NA	51	NA
Tax	I	40	(97.5)%	13	(92.3)%
Profit After tax	(10)	78	NA	38	NA
PAT Margins (%)	NA	5.44%	NA	3.14%	NA
Other Comprehensive Income	(1)	(3)	NA	-	NA
Total Comprehensive Income	(11)	75	NA	38	NA
Diluted EPS (INR)	(0.08)	0.65	NA	0.31	NA

\* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)

### HI-FY2I Standalone Income Statement (Ind-AS)



Income Statement (Mn)	HI-FY2I	HI-FY20	Y-o-Y
Operational Revenue	2,679	2,871	(6.7)%
Total Expenses	2,446	2,554	(4.2)%
Operational EBITDA	233	317	(26.5)%
Operational EBITDA Margins (%)	8.70%	11.04%	(234) Bps
Adjusted EBITDA*	302	317	(4.7)%
Adjusted EBITDA Margins (%)	11.27%	11.04%	23 Bps
Other Income	23	56	(58.9)%
Depreciation	64	56	14.3%
Finance Cost	145	144	0.7%
Exceptional Items	5	31	(83.9)%
РВТ	42	142	(70.4)%
Tax	4	47	(70.2)%
Profit After tax	28	95	(70.5)%
PAT Margins (%)	1.05%	3.31%	(226) Bps
Other Comprehensive Income	(1)	(4)	NA
Total Comprehensive Income	27	91	(70.3)%
Diluted EPS (INR)	0.22	0.78	(71.8)%

EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)

# Q2-FY21 Consolidated Income Statement (Ind-AS)



Income Statement (INR Mn)	Q2-FY21	Q2-FY20	Y-o-Y	QI-FY2I	Q-0-Q
Operational Revenue	2,568	2,223	15.5%	3,057	(16.0)%
Total Expenses	2,232	1,922	16.1%	2,547	(12.4)%
Operational EBITDA	336	301	11.6%	510	(34.1)%
Operational EBITDA Margins (%)	13.08%	13.54%	(46) Bps	16.68%	(360) Bps
Adjusted EBITDA*	425	311	36.7%	543	(21.7)%
Adjusted EBITDA Margins (%)	16.55%	13.99%	256 Bps	17.76%	(121) Bps
Other Income	13	6	116.7%	5	160.0%
Depreciation	96	77	24.7%	95	1.1%
Finance Cost	81	144	(43.8)%	105	(22.9)%
Share of profit/ loss of associate	-	-	NA	-	NA
РВТ	172	86	100.0%	315	(45.4)%
Tax	75	П	NA	109	(31.2)%
Profit After Tax	97	75	29.3%	206	(52.9)%
PAT Margins (%)	3.78%	3.37%	41 Bps	6.74%	(296) Bps
Other Comprehensive Income	42	(56)	NA	46	(8.7)%
Total Comprehensive Income	139	19	NA	252	(44.8)%
Diluted EPS (INR)	0.46	0.57	(19.3)%	1.27	(63.8)%

\* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)

## HI-FY2I Consolidated Income Statement (Ind-AS)



Income Statement (Mn)	HI-FY2I	HI-FY20	Y-o-Y
Operational Revenue	5,626	4,824	16.6%
Total Expenses	4,778	4,168	14.6%
Operational EBITDA	848	656	29.3%
Operational EBITDA Margins (%)	15.07%	13.60%	147 Bps
Adjusted EBITDA*	968	669	44.7%
Adjusted EBITDA Margins (%)	17.21%	13.87%	334 Bps
Other Income	17	13	30.8%
Depreciation	191	153	24.8%
Finance Cost	187	204	(8.3)%
Exceptional Items	-	-	NA
РВТ	487	312	56.1%
Tax	185	72	NA
Profit After tax	302	240	25.8%
PAT Margins (%)	5.37%	<b>4.98</b> %	39 Bps
Other Comprehensive Income	89	(56)	NA
Total Comprehensive Income	391	184	NA
Diluted EPS (INR)	1.64	1.85	(11.4)%

\* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)




### COUNTRY OVERVIEW

### **CFS** India



- R&D Centre at Tarapur that has developed many new Diphenol-downstream products
- Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries
- Provides technical expertise and support for shelf life solutions and aroma ingredients to the various laboratories of CFS located globally



### **CFS** Mexico



- Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016
- Primarily manufactures Blends and Additives
- Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Pre-mix
- Total Market size is ~USD 200 Mn and CFS Mexico enjoys an overall market share of ~15% giving enough growth opportunities
- CFS Antioxidantes De Mexico S.A.de C.V, the holding company has been reversed merged with effect from February 1, 2019 into Dresen Quimica S.A.P.I de C.V, Mexico
   Operational Revenue (INR Mn)



# **CFS** Europe

### **Performance Chemicals**

- Acquired the manufacturing facility at Ravenna, Italy in 2011, which provides captive requirements of key raw materials i.e. Hydroquinone ٠ and Catechol
- Capacity utilization achieved at 95% in FY19 ٠
- Considerable growth in EBITDA Margins & Profits due to favourable prices and better yields ٠

### Shelf Life Solutions

- Application lab commenced in October 2018 ٠
- The Blending plant was commissioned in March 2019 ٠
- Dedicated Sales team being appointed to cover the entire European market ٠
- **On-boarded 5 customers**

#### **Operational Revenue (INR Mn)**








### **CFS Brazil**


### **Shelf Life Solutions**

- Formed in 2013 for Blends and the production started in 2015
- Has an application lab in Indaiatuba Brazil for customizing blends for Shelf-life Extension Solutions.
- Handles distribution of bulk antioxidants and vanillin.
- Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Pre-mix and Bio Diesel
- Dedicated facility for animal feed and pet food additives.
- Revenue will continue to grow due to launch of new products in animal nutrition and better penetration of markets

### Operational Revenue (INR Mn)



#### Quarterly Operational Revenue (INR Mn)







# **CFS** Wanglong

- CFS along with CFS Europe acquired 51% stake in Ningbo Wanglong Flavours in 2017 which had an operational plant since 2011
- This acquisition makes CFS the 3<sup>rd</sup> largest producer of Vanillin
- Located in Grade I Industrial zone in the city of Yuyao Zhejiang Province, China.
- It manufactures Vanillin through a dedicated manufacturing facility which started at the end of Q2-FY18
- With capacity expansion of Guaiacol in India, we are covered for 100% of primary raw material
- Establishing a distribution network across the globe



#### **Operational Revenue (INR Mn)**



# **CFS North America**

### Shelf Life Solutions

Formed in October 2015 as a wholly owned subsidiary


### Market focus

- Food Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants) •
- **Pet food** Rendering for pet food (natural antioxidants), Rendering for animal feed (synthetic antioxidants) •
- Animal feed Antioxidants, Mould Inhibitors, Gut Health Probiotics, Others ٠
- Has launched new products in natural anti-oxidants and animal nutrition ٠
- Built a strong diversified portfolio of 40+ products ٠





#### **Operational Revenue (INR Mn)**





### HISTORICAL FINANCIAL OVERVIEW

### Historical Standalone Income Statement



Particulars (INR Mn)	FY18	FY19	FY20	HI-FY2I
Operational Income	4,050	5,481	5,798	2,679
Total Expenses	3,996	5,182	5,201	2,446
EBITDA	54	299	597	233
EBITDA Margin	1.33%	5.46%	10.30%	8.70%
Depreciation	91	91	113	64
Finance Cost	236	203	281	145
Other Income	92	137	241	23
Exceptional Items	-	-	31	5
РВТ	(181)	142	413	42
Tax	(39)	35	106	14
Profit After Tax	(142)	107	307	28
PAT Margin	NA	1.95%	5.29%	1.05%
Other Comprehensive Income	I	(3)	(3)	(1)
Total Comprehensive Income	(141)	104	304	27
Diluted EPS (INR per share)	(1.63)	0.88	2.53	0.22

# Standalone Balance Sheet

Particulars (INR Mn)	FY19	FY20	HI-FY2I	Particulars (INR Mn)	FY19	FY20	HI-FY2I
EQUITY	3,474	3,768	4,367	Non-Current Assets	2,733	3,802	3,812
a) Equity Share Capital	121	121	121	a) Property, Plant and Equipment	789	686	2,419
b) Other Equity	3,353	3,647	4,246	b) Capital Work In Progress	523	1,742	65
c) Non-Controlling Interest	-	-	-	c) Right-Of-Use Assets	-	246	235
	1,149	1,240	I,267	d) Investment Property	21	21	21
Non-Current Liabilities	,	, -		e) Other Intangible Assets	6	4	243
Financial Liabilities				f) Intangible Assets under Development	161	240	-
a) Borrowings	1,111	1,130	1,156	g) Financial Assets (i) Investments	657	740	735
b) Lease Liabilities	1,111	50	45	(i) Loans	288	36	31
	- 24	28	28	(iii) Other Financial Assets	200	- 50	2
c) Provisions	24			h) Deferred tax assets (Net)	12		-
d) Deferred Tax Liabilities (Net)	-	21	29	i) Income Tax Assets	36	33	35
e) Other Non-Current Liabilities	14	11	9	j) Other Non-Current assets	240	54	26
Current Liabilities	3,187	3,905	4,329	Current Assets	5,075	5,112	6,151
a) Financial Liabilities				a) Inventories	1,093	972	1,424
(i) Borrowings	۱,990	2,184	2,229	b) Financial Assets			
(ii) Trade Payables	1,059	1,330	1,718	(i) Investments	33	-	-
(iii) Other Financial Liabilities	115	250	265	(ii) Trade Receivables	2,619	3,235	3,271
(iv) Lease Liabilities	-	10	10	(iii) Cash and Cash Equivalents	189	7	365
b) Other Current Liabilities	15	61	66	(iv) Other Bank balances	502	124	323
c) Provisions	3	4	12	(v) Loans	159	301	300
d) Current Tax Liabilities (Net)	3	66	29	(vi) Other financial assets	221	235	203
	J			c) Other Current Assets	259	237	265
<b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b>	7,808	8,913	9,963	GRAND TOTAL – ASSETS	7,808	8,913	9,963

### Historical Consolidated Income Statement



PARTICULARS (INR Mn)	FY18	FY19	FY20	HI-FY2I
Operational Income	7,228	8,922	10,491	5,626
Total Expenses	7,102	8,235	9,184	4,778
EBITDA	126	687	1,307	848
EBITDA Margin	1.74%	7.70%	12.46%	15.07%
Depreciation	267	290	328	191
Finance Cost	284	367	431	187
Other Income	116	138	34	17
Income from Associate	2	(1)	-	-
РВТ	(307)	167	582	487
Tax	(68)	137	284	185
Profit After Tax	(240)	30	298	302
PAT Margin	-	0.34%	2.84%	5.37%
Other Comprehensive Income	124	5	13	89
Total Comprehensive Income	(116)	35	311	391
Diluted EPS (INR per share)	(3.01)	0.05	2.50	I.64

### Consolidated Balance Sheet




PARTICULARS (INR Mn)	FY19	FY20	HI-FY2I	PARTICULARS (INR Mn)	FY19	FY20	HI-FY2I
EQUITY	4,303	4,601	5,540	Non-Current Assets	4,143	5,591	5,576
a) Equity Share Capital	121	121	2	a) Property, Plant and Equipment	2,055	2,034	3,738
b) Other Equity	3,588	3,910	4,769	b) Capital Work In Progress	573	1,761	117
, , ,				c) Right-Of-Use Assets	-	338	325
c) Non-Controlling Interest	594	570	650	d) Investment Property	21	21	21
LIABILITIES				e) Goodwill	444	444	444
Non-Current Liabilities	1,961	2,261	2,427	f) Intangible Assets	205	221	243
Financial Liabilities				g) Intangible Assets under Development	17	27	-
	1,936	2,115	2,281	h) Investment in Associate	I	I	<u> </u>
a) Borrowings	1,730			i) Financial Assets			
b) Lease Liabilities	-	97	90	(i) Investments	71	72	71
c) Provisions	24	28	27	(ii) Loans		123	128
d) Deferred Tax Liabilities (Net)	I	21	29	(iii) Other Financial Assets	0	0	2
Current Liabilities	4,604	5,478	5,089	j) Deferred tax assets (Net)	412	407	359
	.,	.,		k) Income Tax Assets	74	66	80
a) Financial Liabilities				I) Other Non-Current assets	159	76	47
(i) Borrowings	2,443	2,781	2,602	Current Assets	6,725	6,749	7,480
(ii) Trade Payables	1,646	1,737	1,425	a) Inventories	2,854	2,981	3,167
(iii) Lease liabilities	-	33	35	b) Financial Assets			
(iii) Other Financial Liabilities	366	672	712	(i) Investments (ii) Trade Receivables	33 2,093	- 2,528	-
b)Other Current Liabilities	73	110	195	(iii) Cash and Cash Equivalents	532	524	2,117
,				(iv) Other Bank balances	502	124	323
c) Provisions	71	79	91	(v) Loans	31	124	10
d)Current Tax Liabilities (Net)	5	66	29	(v) Doards (vi) Other financial assets	108	117	10
<b>GRAND TOTAL - EQUITIES &amp;</b>	10.949	12 240	12.057	c) Other Current Assets	572	464	533
LIABILITES	10,868	12,340	13,057	GRAND TOTAL – ASSETS	10,868	12,340	13,056




### Consolidated Financial Highlights


#### **Operational Revenue (INR Mn)**




Net Debt to Equity



EBITDA (INR Mn) & EBITDA Margin (%)




Net Worth (INR Mn)




### Capital Markets





Price Data (30 <sup>th</sup> September, 2020)	INR
Face Value	1.0
Market Price	114.0
52 Week H/L	114.0/33.4
Market Cap (Mn)	13,826.5
Equity Shares Outstanding (Mn)	121.3
I Year Avg Trading Volume ('000)	631.7

Shareholding Pattern as on 30<sup>th</sup> September, 2020



### Disclaimer



#### Camlin Fine Sciences Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Camlin Fine Science Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

#### Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

#### For further details, please feel free to contact our Investor Relations Representatives:

VALOREM ADVISORS

Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903 9500 Email: camlin@valoremadvisors.com